Analytical Data
-
Gene name
BIRC1
- Application
-
Alternative Names
Baculoviral IAP repeat containing 1; Baculoviral IAP repeat-containing Protein 1; BIRC 1; BIRC1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13075
-
Expression Region
60-345aa
-
AA Sequence
EAKRLKTFVTYEPYSSWIPQEMAAAGFYFTGVKSGIQCFCCSLILFGAGLTRLPIEDHKRFHPDCGFLLNKDVGNIAKYDIRVKNLKSRLRGGKMRYQEEEARLASFRNWPFYVQGISPCVLSEAGFVFTGKQDTVQCFSCGGCLGNWEEGDDPWKEHAKWFPKCEFLRSKKSSEEITQYIQSYKGFVDITGEHFVNSWVQRELPMASAYCNDSIFAYEELRLDSFKDWPRESAVGVAALAKAGLFYTGIKDIVQCFSCGGCLEKWQEGDDPLDDHTRCFPNCPFL
-
Molecular Weight
48.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BIRC1, also known as X-linked inhibitor of apoptosis protein (XIAP), plays a crucial role in the regulation of apoptosis and cell survival pathways. It belongs to the inhibitor of apoptosis (IAP) family and is primarily known for its ability to inhibit caspases, which are critical proteases in the execution of programmed cell death. The dysregulation of BIRC1 has been implicated in various pathological conditions, including cancer, where its overexpression can lead to tumorigenesis and resistance to therapies. Recent studies have shown that BIRC1 can also modulate inflammatory responses and is involved in several signaling pathways, making it a key player in immune response. Given its significant role in these processes, the investigation of recombinant BIRC1 protein has gained traction, focusing on its structural and functional properties to better understand its mechanism of action. Researchers are employing recombinant DNA technology to produce BIRC1 in various expression systems, enabling them to study its interactions with other proteins and small molecules that may inhibit its activity. This research has potential therapeutic implications, as targeting BIRC1 with specific inhibitors could enhance the efficacy of cancer treatments and restore normal apoptotic processes in affected cells. Understanding the nuances of BIRC1's function could pave the way for novel intervention strategies in diseases where apoptosis regulation is disrupted.
